Search Result

Results for "

FPR1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Formyl Peptide Receptor (FPR) (24) Apoptosis (5) Bacterial (2) Bombesin Receptor (3) Cadherin (1) Calcium Channel (2) Collagen (1) CXCR (1) FXR (1) Interleukin Related (1) NF-κB (1) NOD-like Receptor (NLR) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Small Interfering RNA (siRNA) (3) TGF-β Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (20) Metabolic Disease (1) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: Formyl Peptide Receptor (FPR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1122

Cyclosporin H 3 Publications Verification	Formyl Peptide Receptor (FPR)	Infection Inflammation/Immunology
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.

HY-101283

HCH6-1 5 Publications Verification	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases ^[1].

HY-156293

FPR1 antagonist 1	Formyl Peptide Receptor (FPR) Apoptosis	Cancer
FPR1 antagonist 1 (compound 24a) is a formyl peptide receptor 1 (FPR1) antagonist with an IC₅₀ of 25 nM. FPR1 antagonist 1 inhibits cell growth through a combined effect on cell proliferation and apoptosis and reduces cell migration, while inducing an increase in angiogenesis ^[1].

HY-19574

FPR Agonist 43 2 Publications Verification	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist ^[1] .

HY-103286

PD176252 2 Publications Verification	Bombesin Receptor	Cancer
PD176252 is a potent antagonist of neuromedin-B preferring (BB₁) and gastrin-releasing peptide-preferring (BB₂) receptor with K_is of 0.17 nM and 1 nM for human BB₁ and BB₂ receptors, and 0.66 nM, 16 nM for Rat BB₁ and BB₂ receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC₅₀s of 0.31 and 0.66 μM in HL-60 cells.

HY-173591

T0080	Formyl Peptide Receptor (FPR) Apoptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
T0080 is a central nervous system-penetrant *FPR1* inhibitor. By functionally blocking the FPR1 signaling pathway, T0080 effectively reduces neutrophil infiltration into ischemic brain tissue and maintains the integrity of the blood-brain barrier. T0080 alleviates tPA-associated hemorrhagic transformation, inhibits demyelination responses and the expression of NOX2. T0080 also possesses anti-apoptotic (apoptosis) and anti-inflammatory properties, thereby protecting myelin and reducing neurological deficits. T0080 is widely used in studies related to ischemic stroke complicated by hemorrhagic transformation after tPA thrombolysis, as well as multiple sclerosis ^[1] .

HY-P1795

Boc-dPhe-Leu-dPhe-Leu-Phe 2 Publications Verification	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
Boc-dPhe-Leu-dPhe-Leu-Phe (Boc-fLfLF) is a selective N-formyl peptide receptor1 (FPR1) antagonist. Boc-dPhe-Leu-dPhe-Leu-Phe inhibits fMIFL(HY-P0224)-induced NADPH oxidase activity. Boc-dPhe-Leu-dPhe-Leu-Phe can be used for the study of inflammation ^[1].

HY-116216

PD 168368	Bombesin Receptor	Cancer
PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the K_i of 15–45 nM ^[1]. PD 168368 is neuromedin B receptor (NMBR; IC₅₀=96 nM) / gastrin-releasing peptide receptor (GRPR IC₅₀=3500 nM) antagonist . PD 168368 also is a mixed *FPR1/FPR2/FPR3* agonist with EC₅₀s of 0.57, 0.24, and 2.7 nM, respectively .

HY-P1117

MMK1 1 Publications Verification	Formyl Peptide Receptor (FPR) Calcium Channel	Neurological Disease Inflammation/Immunology
MMK1 is a potent and selective human formyl peptide receptor like-1 (FPRL-1/FPR2) agonist with EC₅₀s of <2 nM and >10000 nM for FPRL-1 and FPR1, respectively. MMK1 is a potent chemotactic and calcium-mobilizing agonist. MMK1 potently activates phagocytic leukocytes and enhances Pertussis Toxin-sensitive production by human monocytes of proinflammatory cytokines IL-1b and IL-6. MMK1 exerts anxiolytic-like activity ^[1] .

HY-128113

AG-09/1	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
AG-09/1 is a specific formyl peptide receptor 1 (FPR1) agonist. N-formyl peptide receptors (FPR) are important in host defense ^[1].

HY-117971

BVT173187	CXCR Formyl Peptide Receptor (FPR)	Others
BVT173187 is a selective inhibitor of the neutrophil formyl peptide receptor FPR1, with activity that inhibits FPR1 activation. BVT173187 inhibits FPR1 agonist-induced activation in neutrophils, reduces adhesion molecule mobilization and superoxide anion production, and has inhibitory activity on FPR1 similar to that of earlier described peptide antagonists, but also has effects on C5aR and CXCR signaling.

HY-P1744

N-Formyl-Met-Leu-Phe-Lys fMLFK	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
N-Formyl-Met-Leu-Phe-Lys (fMLFK) is a peptide, acts as a potent and selective agonist of *FPR1, with EC₅₀s of 3.5 nM, 6.7 μM and 0.88 μM for FPR1, FPR2 and FPR*2-D281 ^7.32G, respectively ^[1].

HY-156294

FPR1 antagonist 2	Formyl Peptide Receptor (FPR) Apoptosis	Cancer
FPR1 antagonist 2 (compound 25b) is a formyl peptide receptor 1 (FPR1) antagonist with an IC₅₀ of 70 nM. FPR1 antagonist 2 inhibits cell growth through a combined effect on cell proliferation and apoptosis and reduces cell migration, while inducing an increase in angiogenesis ^[1].

HY-P2355

BOC-FlFlF BOC2; Boc-Phe-dLeu-Phe-dLeu-Phe	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
BOC-FlFlF (Boc-Phe-dLeu-Phe-dLeu-Phe) is a selective *FPR1* antagonist. Boc-FlFlF has an apparent dissociation constant (K_D) of 230 nM as determined by the intracellular calcium mobilization assay. Boc-FlFlF can be used for the study of inflammation ^[1] .

HY-P1121A

WKYMVM-NH2 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase ^[1] .

HY-144604

FPR2 agonist 2	Formyl Peptide Receptor (FPR)	Infection Neurological Disease
FPR2 agonist 2 is a potent and CNS-penetrant *FPR2* agonist with an EC₅₀ of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity ^[1].

HY-P1116A

PBP10 TFA 1 Publications Verification	Bacterial	Infection Inflammation/Immunology
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 ^[1]. PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .

HY-P10738

N-Formyl-MMYALF	Formyl Peptide Receptor (FPR)	Infection
N-Formyl-MMYALF is a potent mitochondrial N-formyl peptide (mtFP) that has the activity of depleting calcium ions in the endoplasmic reticulum. N-Formyl-MMYALF can inhibit the *FPR-1*-mediated chemotactic response of polymorphonuclear leukocytes (PMNs) to bacterial peptides ^[1].

HY-N8152

Randialic acid B	Reactive Oxygen Species (ROS)	Inflammation/Immunology
Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks *FPR1* in human neutrophils and attenuates psoriasis-like inflammation in vivo ^[1].

HY-P1118

Ac9-25	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .

HY-176403

FPR1 antagonist 3	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
FPR1 antagonist 3 (compound 10) is a potent and selective *FPR1* antagonist. FPR1 antagonist 3 inhibits superoxide anion generation and elastase release with IC₅₀s of 0.33 and 0.84 μM, respectively ^[1].

HY-RS05085

FPR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FPR1 Human Pre-designed siRNA Set A contains three designed siRNAs for FPR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FPR1 Human Pre-designed siRNA Set A FPR1 Human Pre-designed siRNA Set A

HY-RS16619

Fpr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fpr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fpr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fpr1 Mouse Pre-designed siRNA Set A Fpr1 Mouse Pre-designed siRNA Set A

HY-RS23054

Fpr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fpr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fpr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fpr1 Rat Pre-designed siRNA Set A Fpr1 Rat Pre-designed siRNA Set A

HY-178919

N-19004	Formyl Peptide Receptor (FPR) Apoptosis Bacterial	Inflammation/Immunology
N-19004 is a *FPR1* antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa ^[1] .

HY-P2355A

BOC-FlFlF TFA BOC2 TFA; Boc-Phe-dLeu-Phe-dLeu-Phe TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
BOC-FlFlF (TFA) (Boc-Phe-dLeu-Phe-dLeu-Phe (TFA)) is a selective *FPR1* antagonist. BOC-FlFlF has an apparent dissociation constant (K_D) of 230 nM as determined by the intracellular calcium mobilization assay. BOC-FlFlF can be used for the study of inflammation ^[1].

HY-101283R

HCH6-1 (Standard)	Formyl Peptide Receptor (FPR) Reference Standards	Inflammation/Immunology
HCH6-1 (Standard) is the analytical standard of HCH6-1 (HY-101283). This product is intended for research and analytical applications. HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases ^[1].

HY-P1117A

MMK1 TFA	Formyl Peptide Receptor (FPR) Calcium Channel	Neurological Disease Inflammation/Immunology
MMK1 TFA is a potent and selective human formyl peptide receptor like-1 (FPRL-1/FPR2) agonist with EC₅₀s of <2 nM and >10000 nM for FPRL-1 and FPR1, respectively. MMK1 TFA is a potent chemotactic and calcium-mobilizing agonist. MMK1 TFA potently activates phagocytic leukocytes and enhances Pertussis Toxin-sensitive production by human monocytes of proinflammatory cytokines IL-1b and IL-6. MMK1 TFA exerts anxiolytic-like activity ^[1] .

HY-P991864

Annexuzlimab MDX-124	Formyl Peptide Receptor (FPR)	Cancer
Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to *ANXA1* disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted *ANXA1, preventing FPR1/2* activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma ^[1] .

HY-P10738A

N-Formyl-MMYALF TFA	Formyl Peptide Receptor (FPR)	Infection
N-Formyl-MMYALF TFA is a mitochondrial N-formyl peptide that has the activity of depleting calcium ions in the endoplasmic reticulum. N-Formyl-MMYALF TFA can inhibit the *FPR-1*-mediated chemotactic response of PMNs to bacterial peptides ^[1].

HY-P1118A

Ac9-25 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor *(FPR)* agonist and activates the neutrophil NADPH oxidase through FPR .

HY-N17383

Ligusticum cycloprolactam	Toll-like Receptor (TLR) NF-κB Collagen Interleukin Related Cadherin NOD-like Receptor (NLR) TGF-β Receptor FXR Apoptosis	Metabolic Disease Inflammation/Immunology
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces *FPR1* expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease ^[1] .

HY-103286R

PD176252 (Standard)	Reference Standards Bombesin Receptor	Cancer
PD176252 (Standard) is the analytical standard of PD176252 (HY-103286). This product is intended for research and analytical applications. PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC₅₀s of 0.31 and 0.66 μM in HL-60 cells.

Cat. No.	Product Name	Target	Research Area